Alzheimer's Second Opinion from Cuba for Michigan Families

A second opinion can be invaluable when navigating Alzheimer's disease — particularly when U.S. treatment options are limited, when the diagnosis is uncertain, or when the family wants to explore alternative approaches.

American families seek second opinions from Cuba's neurology team for several reasons: FDA-approved treatments (lecanemab, donanemab) are limited to mild Alzheimer's — for patients whose disease has progressed beyond the mild stage, U.S. options are primarily symptom management. Cuba offers NeuroEPO research and intensive rehabilitation for mild-to-moderate Alzheimer's. Additionally, CIREN's 4–6 hours of daily multidisciplinary therapy is not available in the U.S. healthcare system.

The second opinion process is simple: submit neuropsychological testing, MRI, blood work, and medication list for review. Cuba's neurology team provides a fresh, independent evaluation of the patient's cognitive stage, imaging, and treatment history — offering a different perspective from the U.S. neurologist. The Cuban medical report is shared with the patient's U.S. physician for coordinated care. Cuba's program is complementary, not substitutive — patients continue their U.S. medications and follow-up.